Gastrointestinal Safety Profile of Selective COX-2 Inhibitors | Kickoff

Gastrointestinal Safety Profile of Selective COX-2 Inhibitors

16 May

The hypothesis that selective COX-2 inhibitors may provide an improved risk- benefit ratio in terms of gastrointestinal safety as compared with conventional NSAIDs was tested in three large phase III clinical trials on a total of 35,000 pa- tients. In the Gastrointestinal Outcomes Research (VIGOR) study (Bombardier et al. 2000) and in the Therapeutic  Arthritis  Research and Gastrointestinal Event Trial (TARGET) (Schnitzer et al. 2004) rofecoxib and lumiracoxib were found to decrease the risk of confirmed gastrointestinal  events (including ul- cerations, bleedings, and perforations) associated with traditional NSAIDs by more than 50%. In the Celecoxib Long-term Arthritis Safety Study (CLASS), however, a significant  beneficial effect of celecoxib was only evident when the definition  of upper  gastrointestinal  endpoints  was expanded  to include symptomatic  ulcers (Silverstein et al. 2000). Moreover, outcomes of the first

6 months were published instead of the complete 1-year data of this study. In addition, both the CLASS and TARGET studies have clearly shown that patients receiving low-dose aspirin for cardiovascular protection  do not benefit from the gastrointestinal safety of these drugs.

Another interesting finding of the past few years was the observation that COX-2 may influence ulcer healing and the associated angiogenesis. In accord with this concept, COX-2 has previously been shown to be induced in tissue

on the edges of ulcers (Mizuno et al. 1997). In animal studies selective COX-2 inhibitors have been demonstrated to retard ulcer healing (Schmassmann et al.

1998). Consequently, it is necessary to test whether effective ulcer healing oc-

curs in patients  with NSAID-associated ulcers switched to selective COX-2 inhibitors.

Cardiovascular Side Effects

Selective COX-2 inhibitors  have been associated with an increased incidence of cardiovascular  side effects. First data  supporting  a respective risk were published in the VIGOR study, where patients receiving rofecoxib had a sig- nificant fourfold increase in the incidence of myocardial infarctions, as com-

pared with patients randomized  to naproxen (Bombardier et al. 2000). There are  several reasons  for  the  fact that  these  results  have not  been  consid- ered  sufficiently. Accordingly, in the CLASS and  TARGET trials  no statis- tically significant  difference  was noted  in the  incidence  of cardiovascular events (cerebrovascular accident, myocardial infarction, angina) between cele- coxib/lumiracoxib and standard NSAIDs (Silverstein et al. 2000; Farkouh et al.

2004). However, in the latter trials patients with osteoarthritis were included. By contrast,  the VIGOR study was performed  on patients  with rheumatoid arthritis,  a condition  that  has  been  associated  with an  enhanced  rate  of cardiovascular  events. Moreover, about  a quarter  of the  patients  included in the CLASS and TARGET trials took aspirin  as a cardioprotective  agent, whereas the entry criteria for the VIGOR study precluded aspirin consump- tion.

2

Recently, long-term studies intended  to find out whether selective COX-2 inhibitors may be used to prevent the formation of adenomatous colon polyps (adenomatous polyposis prevention study with rofecoxib: APPROVe; adenoma prevention with celecoxib: APC) or Alzheimer’s disease (Alzheimer’s Disease anti-inflammatory Prevention  Trial: ADAPT) have shown that selective and nonselective  COX inhibitors  may increase  the incidence  of cardiac  infarc- tions  and  other  cardiovascular  reactions  (NIH 2004; Bresalier et al. 2005; Solomon et al. 2005). In these studies, the effect became fully evident only after treatment  for more than 1 1  years in otherwise healthy patients. More- over, in high-risk  patients  short-term treatment  with valdecoxib/parecoxib was associated with an increased rate of severe thromboembolic  events (Ott et al. 2003; Nussmeier et al. 2005). These observations had variable pharma- copolitical consequences including the withdrawal of rofecoxib (Vioxx) and valdecoxib (Bextra) from the market.  Moreover, the outcome  of these tri- als prompted  regulatory  bodies to request  changes in the labeling of both selective and nonselective COX inhibitors, including those available for over- the-counter  use (FDA 2005). Consequently, until proof of the opposite, all of these drugs are believed to go along with, at least in long-term  use, an in- creased cardiovascular risk. To minimize this risk, the respective substances should be taken at the lowest effective dose for the shortest  possible dura- tion of treatment  (European Agency for the Evaluation of Medicinal Products

2005a, b).

Scientifically these observations pose new questions: It has been assumed before that selective COX-2 inhibitors that do not inhibit platelet COX-1 might unfavorably alter the thromboxane/prostacyclin balance by inhibiting exclu- sively COX-2-dependent synthesis of vasoprotective prostacyclin in endothe- lial cells (Cheng et al. 2002). In fact, prostacyclin  is a potent  inhibitor  of platelet aggregation, activation, and adhesion  of leukocytes, and accumula- tion of cholesterol in vascular cells. Recent evidence, however, supports  the view that disturbance of the thromboxane/prostacyclin balance cannot be the sole mechanism conferring the cardiovascular risk of COX-2 inhibitors.  Ac-

cordingly, patients  with coronary artery bypass grafting experienced severe cardiovascular events by valdecoxib/parecoxib, albeit apparently protected by low-dose aspirin (Ott et al. 2003; Nussmeier et al. 2005). Likewise, a subgroup analysis from the APC trial has demonstrated that aspirin may not abrogate the potential cardiovascular harm of celecoxib (Solomon et al. 2005). More- over, given that in all long-term studies with coxibs and NSAIDs performed so far, an increased cardiovascular risk became evident after prolonged drug administration only, it appears  feasible that  a permanent  COX-2 blockade may play a crucial role in the development  of cardiovascular  events. In line with this concept, COX-2-derived prostaglandins  have been shown recently to upregulate  the expression of the thrombin  inhibitor  thrombomodulin in human smooth muscle cells, thus providing a molecular basis for a hitherto unknown platelet-independent mechanism underlying the prothrombotic ef- fects of both selective and nonselective COX-2 inhibitors (Rabausch et al. 2005). In this context it is also noteworthy  that the traditional  NSAID diclofenac, given as a retarded form, elicits a more pronounced inhibition of intravascular COX-2-dependent prostaglandin formation as compared to rofecoxib and cele- coxib (Hinz et al. 2006). Finally, a recently published population-based nested case-control  analysis has shown an increased  risk of myocardial  infarction associated with the current use of both selective (rofecoxib) and nonselective (diclofenac, ibuprofen) COX-2 inhibitors (Hippisley-Cox and Coupland 2005). Even though the methodology used in this study has been called in question, a potentially increased risk of traditional  NSAIDs in eliciting myocardial in- farctions warrants attention.  Consequently, the cardiovascular safety of both selective COX-2 inhibitors  and conventional NSAIDs should be reconsidered in future studies.

Although myocardial infarctions provide valuable data concerning cardio- vascular safety of drugs, the cardiorenal profiles of NSAIDs and selective COX-2 inhibitors  have also to be considered. As a matter of fact, the involvement of COX-2 in human renal function is supported by numerous clinical studies that showed that selective COX-2 inhibitors,  similar to other NSAIDs, may cause peripheral  edema, hypertension,  and exacerbation of pre-existing hyperten- sion by inhibiting  water and salt excretion by the kidneys (Catella-Lawson et al. 1999; Whelton et al. 2000; Schwarz et al. 2000). These observations are of immense importance given that relatively small changes in blood pressure could have a significant  impact  on cardiovascular  events. In patients  with osteoarthritis, increases in systolic blood pressure  of 1–5 mmHg have been associated  with 7,100–35,700 additional  ischemic heart  disease and  stroke events over 1 year (Singh et al. 2003). Likewise, the hypertension  optimal treatment  (HOT) study showed that diastolic blood pressure  differences of

+4 mmHg can lead to a 28% increase in myocardial  infarctions  (Hansson et al. 1998).

Future Developments

The available traditional antipyretic analgesics and selective COX-2 inhibitors still leave space for additional compounds. For acute pain a compound that is absorbed fast, fully bioavailable, and eliminated quickly (such as ibuprofen) might be of interest.

Inhibiting COX-1, COX-2, and 5-lipoxygenase (5-LOX) may be rewarding for the treatment  of osteoarthrosis.  The advantage of such compounds would

be that  they are not  associated  with alternative  processing  of arachidonic acid via the 5-LOX pathway. In fact, leukotrienes  generated  by 5-LOX may cause adhesion of neutrophils and vasoconstriction, resulting in ischemia and

consequently mucosal lesions. A compound claimed to be endowed with such dual COX-/LOX-inhibitory properties is licofelone (ML3000) (Tries et al. 2002). However, clinical data supporting  the claims are still scarce. Likewise, nitric

oxide (NO)-releasing NSAIDs are widely discussed. They are hoped to protect the gastrointestinal  tract by releasing vasodilatory NO and to produce the full therapeutic effects of, e.g., diclofenac or naproxen (Wallace 2002).

So far, hard  clinical data are missing despite many years of research.  It

is also unclear how patients  and physicians will solve the dosing problems of such compounds,  which release two active ingredients  (NO and NSAID) with different  pharmacokinetic and toxicological properties.  The microso- mal prostaglandin  E synthase I that is coexpressed with COX-2 under diverse inflammatory  conditions  may represent  a potential  target  for treatment  of inflammatory  pain (Jakobsson et al. 1999). From the pharmacological point of view an inhibition  of this enzyme would open the opportunity to inhibit the production  of COX-2-dependent proinflammatory PGE2 without a con- comitant  blockade of COX-2-dependent prostacyclin, which confers various protective actions in the cardiovascular  and renal system. Finally, targeting of individual PG receptor  subtypes may permit a separation  of desired and unwanted  effects of NSAIDs. Recently, blockade of the EP2 receptor  has at- tracted  attention  as a possible target  for centrally acting, antihyperalgesic agents (Reinold et al. 2005).

References

Ahmadi S, Lippross S, Neuhuber WL, Zeilhofer HU (2002) PGE2 selectively blocks inhibitory glycinergic neurotransmission onto rat superficial dorsal horn neurons. Nat Neurosci

5:34–40

Akopian AN, Sivilotti L, Wood JN (1996) A tetrodotoxin-resistant voltage-gated sodium channel expressed by sensory neurons. Nature 379:257–262

Anonymous (1998) An epidemiologic study of severe anaphylactic and anaphylactoid reac- tions among hospital patients: methods and overall risks. The International Collabora- tive Study of Severe Anaphylaxis. Epidemiology 9:141–146

Baba H, Kohno T, Moore KA, Woolf CJ (2001) Direct activation of rat spinal dorsal horn neurons by prostaglandin E2 . J Neurosci 21:1750–1756

Beiche F, Scheuerer S, Brune K, Geisslinger G, Goppelt-Struebe M (1996) Upregulation of

cyclooxygenase-2 mRNA in the rat spinal cord following peripheral inflammation. FEBS Lett 390:165–169

Benn SC, Costigan M, Tate S, Fitzgerald M, Woolf CJ (2001) Developmental expression of

the TTX-resistant voltage-gated sodium channels Nav1.8 (SNS) and Nav1.9 (SNS2) in primary sensory neurons. J Neurosci 21:6077–6085

Bombardier C, Laine L, Reicin A, Shapiro D, Burgos-Vargas R, Davis B, Day R, Ferraz MB, Hawkey CJ, Hochberg MC, Kvien TK, Schnitzer TJ (2000) Comparison  of upper  gas- trointestinal  toxicity of rofecoxib and naproxen  in patients with rheumatoid  arthritis. VIGOR Study Group. N Engl J Med 343:1520–1528

Boutaud O, Aronoff DM, Richardson JH, Marnett LJ, Oates JA (2002) Determinants  of the cellular specificity of acetaminophen as an inhibitor of prostaglandin H2 synthases. Proc Natl Acad Sci USA 99:7130–7135

Brandt K (2003) Paracetamol  in the treatment  of osteoarthritis pain. Drugs 63 Spec No

2:23–41

Bresalier RS, Sandler RS, Quan H, Bolognese JA, Oxenius B, Horgan K, Lines C, Riddell R, Morton D, Lanas A, Konstam MA, Baron JA (2005) Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention  trial. N Engl J Med 352:1092–1102

Bridger S, Henderson K, Glucksman E, Ellis AJ, Henry JA, Williams R (1998) Deaths from low dose paracetamol poisoning. BMJ 316:1724–1725

Brune K (1974) How aspirin  might work: a pharmacokinetic approach.  Agents Actions

4:230–232

Brune K, Hinz B (2004) Selective cyclooxygenase-2 inhibitors: similarities and differences.

Scand J Rheumatol 33:1–6

Brune K, Lanz R (1985) Pharmacokinetics  of non-steroidal  anti-inflammatory drugs. In: Bonta IL, Bray MA, Parnham MJ (eds) The pharmacology of inflammation. (Handbook of inflammation, vol 5) Elsevier Science, Amsterdam, pp 413–449

Brune K, Zeilhofer HU (2006) Antipyretic analgesics: basic aspects. In: Wall PD, Melzack R (eds) Textbook of pain. Elsevier, London

Brune K, Glatt M, Graf P (1976) Mechanism of action of anti-inflammatory drugs. Gen

Pharmacol 7:27–33

Brune K, Rainsford KD, Schweitzer A (1980) Biodistribution  of mild analgesics. Br J Clin

Pharmacol 10 Suppl 2:279–284

Catella-Lawson F, McAdam B, Morrison BW, Kapoor S, Kujubu D, Antes L, Lasseter KC, Quan H, Gertz BJ, FitzGerald GA (1999) Effects of specific inhibition of cyclooxygenase-

2 on sodium balance, hemodynamics, and vasoactive eicosanoids. J Pharmacol Exp Ther

289:735–741

Catella-Lawson F, Reilly MP, Kapoor SC, Cucchiara AJ, DeMarco S, Tournier  B, Vyas SN, FitzGerald GA (2001) Cyclooxygenase inhibitors and the antiplatelet effects of aspirin. N Engl J Med 345:1809–1817

Caterina MJ, Leffler A, Malmberg AB, Martin WJ, Trafton J, Petersen-Zeitz KR, Koltzen- burg M, Basbaum AI, Julius D (2000) Impaired nociception and pain sensation in mice lacking the capsaicin receptor. Science 288:306–313

Chandrasekharan NV, Dai H, Roos KL, Evanson NK, Tomsik J, Elton TS, Simmons DL (2002) COX-3, a cyclooxygenase-1 variant inhibited by acetaminophen  and other anal- gesic/antipyretic  drugs: cloning, structure,  and expression.  Proc Natl Acad Sci USA

99:13926–13931

Cheng Y, Austin SC, Rocca B, Koller BH, Coffman TM, Grosser T, Lawson JA, FitzGerald GA (2002) Role of prostacyclin in the cardiovascular response to thromboxane  A2 . Science

296:539–541

Davis JB, Gray J, Gunthorpe MJ, Hatcher JP, Davey PT, Overend P, Harries MH, Latcham J, Clapham C, Atkinson K, Hughes SA, Rance K, Grau E, Harper AJ, Pugh PL, Rogers DC, Bingham S, Randall A, Sheardown SA (2000) Vanilloid receptor-1 is essential for inflam- matory thermal hyperalgesia. Nature 405:183–187

Dinchuk JE, Liu RQ, Trzaskos JM (2003) COX-3: in the wrong frame in mind. Immunol Lett

86:121

England S, Bevan S, Docherty RJ (1996) PGE2 modulates the tetrodotoxin-resistant sodium current in neonatal rat dorsal root ganglion neurones via the cyclic AMP-protein kinase A cascade. J Physiol (Lond) 495:429–440

European Agency for the Evaluation of Medicinal Products (2005a) Public statement: Euro- pean medicines agency concludes action on COX-2 inhibitors. London, 27 June 2005

European Agency for the Evaluation of Medicinal Products (2005b) EMEA, press release: European Medicines Agency update on non-selective NSAIDs. London, 17 October 2005

Farkouh   ME,  Kirshner   H,  Harrington   RA,  Ruland  S,  Verheugt  FW,  Schnitzer  TJ, Burmester GR, Mysler E, Hochberg MC, Doherty M, Ehrsam E, Gitton X, Krammer G, Mellein B, Gimona A, Matchaba P, Hawkey CJ, Chesebro JH, et al (2004) Comparison of lumiracoxib with naproxen and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET), cardiovascular outcomes: randomised controlled trial. Lancet 364:675–684

FDA (2006) FDA News: FDA announces  series of changes to the class of marketed  non-

steroidal anti-inflammatory drugs (NSAIDs). http://www.fda.gov/bbs/topics/news/2005/NEW01171.html. Cited 8 Apr 2006

Geba GP, Weaver AL, Polis AB, Dixon ME, Schnitzer TJ, et al (2002) Efficacy of rofecoxib, celecoxib, and acetaminophen in osteoarthritis of the knee: a randomized  trial. JAMA

287:64–71

Geisslinger G, Menzel S, Wissel K, Brune K (1993) Single dose pharmacokinetics of different formulations of ibuprofen and aspirin. Drug Invest 5:238–242

Gold MS, Reichling DB, Shuster MJ, Levine JD (1996) Hyperalgesic agents increase a tetrodo- toxin-resistant Na+ current in nociceptors. Proc Natl Acad Sci USA 93:1108–1112

Hansson L, Zanchetti A, Carruthers SG, Dahlof B, Elmfeldt D, Julius S, Menard J, Rahn KH, Wedel H, Westerling S (1998) Effects of intensive blood-pressure lowering and low-dose aspirin  in patients  with hypertension:  principal  results of the Hypertension  Optimal Treatment (HOT) randomised trial. HOT Study Group. Lancet 351:1755–1762

Harvey RJ, Depner UB, Wassle H, Ahmadi S, Heindl C, Reinold H, Smart TG, Harvey K, Schutz B, Abo-Salem OM, Zimmer A, Poisbeau P, Welzl H, Wolfer DP, Betz H, Zeil- hofer HU, Muller U (2004) GlyR α3: an essential target for spinal PGE2 -mediated inflam- matory pain sensitization. Science 304:884–887

Henry D, Lim LL, Garcia Rodriguez LA, Perez Gutthann S, Carson JL, Griffin M, Savage R, Logan R, Moride Y, Hawkey C, Hill S, Fries JT (1996) Variability in risk of gastroin- testinal complications with individual non-steroidal anti-inflammatory drugs: results of a collaborative meta-analysis. Br Med J 312:1563–1566

Hinz B, Brune K (2002) Cyclooxygenase-2—ten years later. J Pharmacol  Exp Ther 300:

367–375

Hinz  B, Brune K, Pahl A (2000a) Cyclooxygenase-2 expression  in  lipopolysaccharide- stimulated human monocytes is modulated by cyclic AMP, prostaglandin  E2 and nons- teroidal anti-inflammatory drugs. Biochem Biophys Res Commun 278:790–796

Hinz B, Brune K, Pahl A (2000b) Prostaglandin  E2 up-regulates cyclooxygenase-2 expres- sion in lipopolysaccharide-stimulated RAW 264.7 macrophages. Biochem Biophys Res Commun 272:744–748

Hinz B, Dorn  CP, Shen TY, Brune K (2000c) Anti-inflammatory–antirheumatic  drugs.

McGuire JL (ed)  Pharmaceuticals—classes,  therapeutic  agents, areas of application, vol 4. Wiley-VCH, Weinheim, pp 1671–1711

Hinz B, Kraus V, Pahl A, Brune K (2000d) Salicylate metabolites inhibit cyclooxygenase-

2-dependent prostaglandin  E2 synthesis in murine macrophages. Biochem Biophys Res

Commun 274:197–202

Hinz B, Rau T, Auge D, Werner U, Ramer R, Rietbrock S, Brune K (2003) Aceclofenac spares cyclooxygenase 1 as a result of limited but sustained biotransformation to diclofenac. Clin Pharmacol Ther 74:222–235

Hinz B, Ramer R, Eichele K, Weinzierl U, Brune K (2004) Upregulation of cyclooxygenase-

2 expression is involved in R(+)-methanandamide-induced apoptotic death of human neuroglioma cells. Mol Pharmacol 66:1643–1651

Hinz B, Chevts J, Renner B, Wuttke H, Rau T, Schmidt A, Szelenyi I, Brune K, Werner U (2005a) Bioavailability of diclofenac potassium  at low doses. Br J Clin Pharmacol 59:

80–84

Hinz B, Rösch S, Ramer R, Tamm E, Brune K (2005b) Latanoprost induces matrix metallo- proteinase-1 expression in human non-pigmented ciliary epithelial cells through a cyclo- oxygenase-2-dependent mechanism. FASEB J 19:1929–1931

Hinz B, Dormann  H, Brune K (2006) More pronounced  inhibition  of cyclooxygenase-2, increase  of blood pressure  and  decrease of heart  rate  by treatment  with diclofenac compared with celecoxib and rofecoxib. Arthritis Rheum 54:282–291

Hippisley-Cox J, Coupland C (2005) Risk of myocardial infarction in patients taking cyclo- oxygenase-2 inhibitors or conventional non-steroidal anti-inflammatory drugs: popula- tion based nested case-control analysis. BMJ 330:1366

Ibanez L, Vidal X, Ballarin E, Laporte JR (2005) Population-based drug-induced  agranulo- cytosis. Arch Intern Med 165:869–874

International Agranulocytosis and Aplastic Anemia Study (1986) Risks of agranulocytosis and aplastic anemia: a first report of their relation to drug use with special reference to analgesics. JAMA 256:1749–1757

Jakobsson  PJ, Thoren  S, Morgenstern  R, Samuelsson B (1999) Identification  of human prostaglandin E synthase: a microsomal, glutathione-dependent, inducible enzyme, con- stituting a potent novel drug target. Proc Natl Acad Sci USA 96:7220–7225

Kaufman DW, Kelly JP, Levy M. Shapiro S (1991) The drug etiology of agranulocytosis an aplastic anemia. Monographs in epidemiology and biostatistics 18. Oxford University Press, London

Kimmey MB (2004) Cardioprotective effects and gastrointestinal risks of aspirin: maintain-

ing the delicate balance. Am J Med 117 Suppl 5A:72S–78S

Kopp E, Ghosh S (1994) Inhibition  of NF-κB by sodium  salicylate and aspirin.  Science

265:956–959

Lopshire JC, Nicol GD (1997) Activation and recovery of the PGE2 -mediated sensitization of the capsaicin response in rat sensory neurons. J Neurophysiol 78:3154–3164

Luong C, Miller A, Barnett J, Chow J, Ramesha C, Browner MF (1996) Flexibility of the NSAID

binding site in the structure of human cyclooxygenase-2. Nat Struct Biol 3:927–933

Maldve RE, Kim Y, Muga SJ, Fischer SM (2000) Prostaglandin E2 regulation of cyclooxyge- nase expression in keratinocytes is mediated via cyclic nucleotide-linked prostaglandin receptors. J Lipid Res 41:873–881

Masferrer JL, Zweifel BS, Seibert S, Needleman P (1990) Selective regulation  of cellular cyclooxygenase by dexamethasone and endotoxin in mice. J Clin Invest 86:1375–1379

Mizuno H, Sakamoto C, Matsuda K, Wada K, Uchida T, Noguchi H, Akamatsu T, Kasuga M (1997) Induction of cyclooxygenase 2 in gastric mucosal lesions and its inhibition by the specific antagonist delays healing in mice. Gastroenterology 112:387–397

Mockenhaupt M, Schlingmann J, Schroeder W, Schoepf E (1996) Evaluation of non-steroidal anti-inflammatory drugs (NSAIDs) and muscle relaxants as risk factors for Stevens- Johnson  syndrome  (SJS) and toxic epidermal  necrolysis (TEN). Pharmacoepidemiol Drug Saf 5:116

Muth-Selbach US, Tegeder I, Brune K, Geisslinger G (1999) Acetaminophen inhibits spinal prostaglandin   E2  release  after  peripheral  noxious  stimulation.  Anesthesiology  91:

231–239

Nantel F, Denis D, Gordon R, Northey A, Cirino M, Metters KM, Chan CC (1999) Distri- bution  and regulation  of cyclooxygenase-2 in carrageenan-induced inflammation.  Br J Pharmacol 128:853–859

Neugebauer V, Geisslinger G, Rümenapp P, Weiretter F, Szelenyi I, Brune K, Schaible HG

(1995) Antinociceptive effects of R(−)- and S(+)-flurbiprofen  on rat spinal dorsal horn neurons rendered hyperexcitable by an acute knee joint inflammation. J Pharmacol Exp Ther 275:618–628

NIH (2004) NIH News. Use of non-steroidal  anti-inflammatory drugs suspended  in large

Alzheimer’s disease prevention  trial. http://www.nih.gov/news/pr/dec2004/od-20.htm. Cited 8 Apr 2006

Niiro H, Otsuka  T, Izuhara  K, Yamaoka K, Ohshima  K, Tanabe  T, Hara  S, Nemoto  Y, Tanaka Y, Nakashima H, Niho Y (1997) Regulation by interleukin-10 and interleukin-4 of cyclooxygenase-2 expression in human neutrophils. Blood 89:1621–1628

Nussmeier  NA, Whelton  AA, Brown MT, Langford RM, Hoeft A, Parlow JL, Boyce SW, Verburg KM (2005) Complications of the COX-2 inhibitors  parecoxib and valdecoxib after cardiac surgery. N Engl J Med 352:1081–1091

Onoe Y, Miyaura C, Kaminakayashiki T, Nagai Y, Noguchi K, Chen QR, Seo H, Ohta H, Nozawa S, Kudo I, Suda T (1996) IL-13 and  IL-4 inhibit  bone  resorption  by sup- pressing cyclooxygenase-2-dependent prostaglandin synthesis in osteoblasts. J Immunol

156:758–764

Ott E, Nussmeier NA, Duke PC, Feneck RO, Alston RP, Snabes MC, Hubbard RC, Hsu PH, Saidman LJ, Mangano DT (2003) Efficacy and safety of the cyclooxygenase 2 inhibitors parecoxib and valdecoxib in patients undergoing coronary artery bypass surgery. J Tho- rac Cardiovasc Surg 125:1481–1492

Patrignani  P, Panara MR, Sciulli MG, Santini G, Renda G, Patrono  C (1997) Differential inhibition  of human  prostaglandin  endoperoxide  synthase-1 and -2 by nonsteroidal anti-inflammatory drugs. J Physiol Pharmacol 48:623–631

Rabausch K, Bretschneider E, Sarbia M, Meyer-Kirchrath J, Censarek P, Pape R, Fischer JW, Schror K, Weber AA (2005) Regulation of thrombomodulin expression in human vascular smooth muscle cells by COX-2-derived prostaglandins. Circ Res 96:e1–6

Ramer R, Weinzierl U, Schwind B, Brune K, Hinz B (2003) Ceramide is involved in R(+)- methanandamide-induced cyclooxygenase-2 expression in human  neuroglioma  cells. Mol Pharmacol 64:1189–1198

Reinold H, Ahmadi S, Depner UB, Layh B, Heindl C, Hamza M, Pahl A, Brune K, Naru-

miya S, Muller U, Zeilhofer HU (2005) Spinal inflammatory hyperalgesia is mediated by prostaglandin E receptors of the EP2 subtype. J Clin Invest 115:673–679

Roujeau JC, Kelly JP, Naldi L, Rzany B, Stern RS, Anderson T, Auquier A, Bastuji-Garin S, Correia O, Locati F, Mockenhaupt M Paoletti C, Shapiro S, Sheir N, Schöpf E, Kaufman D (1995) Drug etiology of Stevens-Johnson syndrome and toxic epidermal necrolysis, first results from an international case-control study. N Engl J Med 333:1600–1609

Rudy AC, Knight PM, Brater DC, Hall SD (1991) Stereoselective metabolism of ibuprofen in humans:  administration of R-, S- and  racemic  ibuprofen.  J Pharmacol  Exp Ther

259:1133–1139

Samad TA, Moore KA, Sapirstein A, Billet S, Allchorne A, Poole S, Bonventre JV, Woolf CJ (2001) Interleukin-1beta-mediated induction of Cox-2 in the CNS contributes to inflam- matory pain hypersensitivity. Nature 410:471–475

Schaible HG, Schmidt RF (1988) Time course of mechanosensitivity  changes in articular afferents during a developing experimental arthritis. J Neurophysiol 60:2180–2195

Schmassmann A, Peskar BM, Stettler C, Netzer P, Stroff T, Flogerzi B, Halter F (1998) Effects of inhibition of prostaglandin endoperoxide synthase-2 in chronic gastro-intestinal ulcer models in rats. Br J Pharmacol 123:795–804

Schnitzer TJ (2002) Update of ACR guidelines for osteoarthritis:  role of the coxibs. J Pain

Symptom Manage 23 Suppl 4:S24–S30

Schnitzer TJ, Burmester GR, Mysler E, Hochberg MC, Doherty M, Ehrsam E, Gitton X, Krammer G, Mellein B, Matchaba P, Gimona A, Hawkey CJ, et al (2004) Comparison of lumiracoxib with naproxen and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal  Event Trial (TARGET), reduction  in ulcer complications: randomised controlled trial. Lancet 364:665–674

Schwab JM, Beiter T, Linder JU, Laufer S, Schulz JE, Meyermann R, Schluesener HJ (2003)

COX-3—a virtual pain target in humans? FASEB J 17:2174–2175

Schwartz JI, Vandormael  K, Malice MP, Kalyani RN, Lasseter KC, Holmes GB, Gertz BJ, Gottesdiener  KM, Laurenzi M, Redfern KJ, Brune K (2002) Comparison  of rofecoxib, celecoxib, and naproxen  on renal function in elderly subjects receiving a normal-salt diet. Clin Pharmacol Ther 72:50–61

Seeff LB, Cuccherini BA, Zimmerman HJ, Adler E, Benjamin SB (1986) Paracetamol hepa-

totoxicity in alcoholics. Ann Intern Med 104:399–404

Silverstein FE, Faich G, Goldstein JL, Simon LS, Pincus T, Whelton A, Makuch R, Eisen G, Agrawal NM, Stenson WF, Burr AM, Zhao WW, Kent JD, Lefkowith JB, Verburg KM, Geis GS (2000) Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: A randomized con- trolled trial.         Celecoxib                Long-term                Arthritis   Safety     Study.                JAMA 284:

1247–1255

Singh G, Miller JD, Huse DM, Pettitt D, D’Agostino RB, Russell MW (2003) Consequences of increased  systolic blood pressure  in patients  with osteoarthritis and  rheumatoid arthritis. J Rheumatol 30:714–719

Smith CJ, Zhang Y, Koboldt CM, Muhammad  J, Zweifel BS, Shaffer A, Talley JJ, Masfer-

rer JL, Seibert K, Isakson PC (1998) Pharmacological analysis of cyclooxygenase-1 in inflammation. Proc Natl Acad Sci U S A 95:13313–13318

Solomon SD, McMurray JJ, Pfeffer MA, Wittes J, Fowler R, Finn P, Anderson WF, Zauber A,

Hawk E, Bertagnolli M (2005) Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention. N Engl J Med 352:1071–1080

Tries S, Neupert W, Laufer S (2002) The mechanism of action of the new antiinflammatory compound ML3000: inhibition of 5-LOX and COX-1/2. Inflamm Res 51:135–143

Vane JR (1971) Inhibition of prostaglandin synthesis as a mechanism of action of aspirin-like drugs. Nat New Biol 231:232–235

Wallace JL, Ignarro LJ, Fiorucci S (2002) Potential cardioprotective actions of NO-releasing aspirin. Nat Rev Drug Discov 1:375–382

Weissmann G (1993) Prostaglandins as modulators rather than mediators of inflammation.

J Lipid Mediat 6:275–286

Werner U, Werner D, Pahl A, Mundkowski R, Gillich M, Brune K (2002) Investigation of the pharmacokinetics of celecoxib by liquid chromatography-mass spectrometry.  Biomed Chromatogr 16:56–60

Werner  U, Werner  D, Rau T, Fromm  MF, Hinz  B, Brune  K (2003) Celecoxib inhibits metabolism  of cytochrome  P450 2D6 substrate  metoprolol  in humans.  Clin Pharma- col Ther 74:130–137

Whelton A, Maurath CJ, Verburg KM, Geis GS (2000) Renal safety and tolerability of cele-

coxib, a novel cyclooxygenase-2 inhibitor. Am J Ther 7:159–175

Winter CA, Risley EA, Nuss GW (1962) Carrageenin-induced edema in hind paw of the rat as an assay for anti-inflammatory drugs. Proc Soc Exp Biol Med 111:544–552

Xie W, Chipman JG, Robertson DL, Erikson RL, Simmons DL (1991) Expression of a mitogen- responsive gene encoding prostaglandin  synthase is regulated by mRNA splicing. Proc Natl Acad Sci USA 88:2692–2696

Xu XM, Sansores-Garcia L, Chen XM, Matijevic-Aleksic N, Du M, Wu KK (1999) Suppression

of inducible cyclooxygenase 2 gene transcription by aspirin and sodium salicylate. Proc

Natl Acad Sci USA 96:5292–5297

Zhang W, Jones A, Doherty M (2004) Does paracetamol (acetaminophen) reduce the pain of osteoarthritis?  A meta-analysis  of randomised  controlled  trials. Ann Rheum Dis

63:901–907

Random Posts

Comments are closed.